FY2026 Earnings Estimate for BMY Issued By Erste Group Bank

Key Points

• Erste Group Bank lowered Bristol Myers Squibb’s FY2026 EPS estimate to $6.34 from $6.96, below the $6.51 consensus forecast and the company’s guidance range of $6.75–$7.00.
• Analyst sentiment is mixed, with BMY carrying an average “Hold” rating and a $64.88 price target. The stock traded near $61.58, while its 4.1% dividend yield and low valuation remain attractive despite concerns about debt and potential earnings declines.
• Bristol Myers Squibb recently beat quarterly earnings and revenue estimates, but investors are weighing pipeline opportunities—including positive breast-cancer trial data and AI collaborations—against safety concerns, legacy-drug erosion and expectations for weaker near-term earnings.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities research analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will earn $6.34 per share for the year, down from their prior estimate of $6.96. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.51 per share.

A number of other research firms have also weighed in on BMY. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Daiwa Securities Group upped their target price on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 4th. Morgan Stanley reaffirmed an "underweight" rating and set a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a report on Wednesday, October 7th. Finally, Leerink Partners cut Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $73.00 to $59.00 in a research report on Monday, October 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of "Hold" and an average price target of $64.88.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $61.58 on Monday. The firm's fifty day moving average is $63.26 and its two-hundred day moving average is $60.34. The firm has a market cap of $125.79 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.31 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company earned $1.46 EPS. Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC grew its holdings in Bristol Myers Squibb by 4.9% in the third quarter. Apollon Wealth Management LLC now owns 109,581 shares of the biopharmaceutical company's stock valued at $6,838,000 after purchasing an additional 5,096 shares during the period. Kingswood Wealth Advisors LLC raised its stake in shares of Bristol Myers Squibb by 15.5% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 41,472 shares of the biopharmaceutical company's stock worth $2,588,000 after buying an additional 5,551 shares during the period. Sigma Planning Corp raised its stake in shares of Bristol Myers Squibb by 11.9% during the 3rd quarter. Sigma Planning Corp now owns 85,287 shares of the biopharmaceutical company's stock worth $5,318,000 after buying an additional 9,036 shares during the period. Bright Futures Wealth Management LLC. lifted its position in shares of Bristol Myers Squibb by 2.9% during the 3rd quarter. Bright Futures Wealth Management LLC. now owns 10,455 shares of the biopharmaceutical company's stock valued at $652,000 after buying an additional 292 shares in the last quarter. Finally, Compass Ion Advisors LLC lifted its position in shares of Bristol Myers Squibb by 28.7% during the 3rd quarter. Compass Ion Advisors LLC now owns 4,829 shares of the biopharmaceutical company's stock valued at $301,000 after buying an additional 1,077 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.